Get a glimpse into our company and investor data—powered by the PitchBook Platform
Royalty on future sales of an ophthalmic suspension drug. The royalty is for Beivance, (besifloxacin ophthalmic suspension), a treatment for bacterial conjunctivitis.
This information is reserved for PitchBook Platform users. To explore Besivance (Royalty Interest)‘s full profile, request access.
© 2019 PitchBook Data. All rights reserved. PitchBook is a financial technology company that provides data on the capital markets.